A citation-based method for searching scientific literature

So Ra Kim, Sang-Guk Lee, Soo Hyun Kim, Jin Hee Kim, Eunhye Choi, Wonhee Cho, John Hoon Rim, Inhwa Hwang, Chan Joo Lee, Minyoung Lee, Chang-Myung Oh, Justin Y Jeon, Heon Yung Gee, Jeong-Ho Kim, Byung-Wan Lee, Eun Seok Kang, Bong-Soo Cha, Myung-Shik Lee, Je-Wook Yu, Jin Won Cho, Jung-Sun Kim, Yong-Ho Lee. Nat Commun 2020
Times Cited: 144



Hiddo J L Heerspink, Bergur V Stefánsson, Ricardo Correa-Rotter, Glenn M Chertow, Tom Greene, Fan-Fan Hou, Johannes F E Mann, John J V McMurray, Magnus Lindberg, Peter Rossing, C David Sjöström, Roberto D Toto, Anna-Maria Langkilde, David C Wheeler. N Engl J Med 2020
Times Cited: 1175




List of shared articles



Times cited

Inhibition of sodium-glucose cotransporter 2 to slow the progression of chronic kidney disease.
Fabie Oguz, Nathalie Demoulin, Jean Paul Thissen, Michel Jadoul, Johann Morelle. Acta Clin Belg 2022
1


Sodium-Glucose Cotransporter 2 Inhibitors and Cardiac Remodeling.
Husam M Salah, Subodh Verma, Carlos G Santos-Gallego, Ankeet S Bhatt, Muthiah Vaduganathan, Muhammad Shahzeb Khan, Renato D Lopes, Subhi J Al'Aref, Darren K McGuire, Marat Fudim. J Cardiovasc Transl Res 2022
2

An Overview of the Cardiorenal Protective Mechanisms of SGLT2 Inhibitors.
Teresa Salvatore, Raffaele Galiero, Alfredo Caturano, Luca Rinaldi, Anna Di Martino, Gaetana Albanese, Jessica Di Salvo, Raffaella Epifani, Raffaele Marfella, Giovanni Docimo,[...]. Int J Mol Sci 2022
8

Anti-inflammatory effect of SGLT-2 inhibitors via uric acid and insulin.
Rosalba La Grotta, Paola de Candia, Fabiola Olivieri, Giulia Matacchione, Angelica Giuliani, Maria Rita Rippo, Elena Tagliabue, Monica Mancino, Francesca Rispoli, Sabina Ferroni,[...]. Cell Mol Life Sci 2022
7

Can SGLT2 inhibitors answer unmet therapeutic needs in chronic kidney disease?
Luca De Nicola, Mario Cozzolino, Simonetta Genovesi, Loreto Gesualdo, Giuseppe Grandaliano, Roberto Pontremoli. J Nephrol 2022
1

Early changes in estimated glomerular filtration rate post-initiation of empagliflozin in EMPEROR-Reduced.
Faiez Zannad, João Pedro Ferreira, John Gregson, Bettina Johanna Kraus, Michaela Mattheus, Sibylle Jenny Hauske, Javed Butler, Gerasimos Filippatos, Christoph Wanner, Stefan D Anker,[...]. Eur J Heart Fail 2022
1

Dapagliflozin for the treatment of chronic kidney disease.
Yu Kurata, Masaomi Nangaku. Expert Rev Endocrinol Metab 2022
0

Mechanisms of cardio-renal protection of sodium-glucose cotransporter-2 inhibitors.
Martina Chiriacò, Domenico Tricò, Anna Solini. Curr Opin Pharmacol 2022
1


Characterization of the SGLT2 Interaction Network and Its Regulation by SGLT2 Inhibitors: A Bioinformatic Analysis.
Zofia Wicik, Anna Nowak, Joanna Jarosz-Popek, Marta Wolska, Ceren Eyileten, Jolanta M Siller-Matula, Dirk von Lewinski, Harald Sourij, Krzysztof J Filipiak, Marek Postuła. Front Pharmacol 2022
0

Glucose-lowering drugs with cardiovascular benefits as modifiers of critical elements of the human life history.
Angelo Avogaro, Saula Vigili de Kreutzenberg, Mario Luca Morieri, Gian Paolo Fadini, Stefano Del Prato. Lancet Diabetes Endocrinol 2022
0

Managing Covid-19 in patients with heart failure: current status and future prospects.
Hawani Sasmaya Prameswari, Iwan Cahyo Santosa Putra, Wilson Matthew Raffaello, Michael Nathaniel, Adrian Sebastian Suhendro, Achmad Fitrah Khalid, Raymond Pranata. Expert Rev Cardiovasc Ther 2022
0


Sodium-Glucose Cotransporter-2 Inhibitors: Impact on Atherosclerosis and Atherosclerotic Cardiovascular Disease Events.
Adam J Nelson, Josephine L Harrington, Ahmed A Kolkailah, Neha J Pagidipati, Darren K McGuire. Heart Fail Clin 2022
0

Repurposing SGLT-2 Inhibitors to Target Aging: Available Evidence and Molecular Mechanisms.
Rosalba La Grotta, Chiara Frigé, Giulia Matacchione, Fabiola Olivieri, Paola de Candia, Antonio Ceriello, Francesco Prattichizzo. Int J Mol Sci 2022
0

Inhibition of sodium-glucose cotransporter 2 suppresses renal stone formation.
Go Anan, Takuo Hirose, Daisuke Kikuchi, Chika Takahashi, Akari Endo, Hiroki Ito, Shigemitsu Sato, Shingo Nakayama, Hideaki Hashimoto, Katsuya Ishiyama,[...]. Pharmacol Res 2022
0


Effects of dapagliflozin on prevention of major clinical events and recovery in patients with respiratory failure because of COVID-19: Design and rationale for the DARE-19 study.
Mikhail Kosiborod, Otavio Berwanger, Gary G Koch, Felipe Martinez, Omar Mukhtar, Subodh Verma, Vijay Chopra, Ali Javaheri, Philip Ambery, Samvel B Gasparyan,[...]. Diabetes Obes Metab 2021
24

Pathophysiology of diabetic kidney disease: impact of SGLT2 inhibitors.
Ralph A DeFronzo, W Brian Reeves, Alaa S Awad. Nat Rev Nephrol 2021
96